BRPI1007452A2 - formulações galênicas de compostos orgânicos - Google Patents

formulações galênicas de compostos orgânicos

Info

Publication number
BRPI1007452A2
BRPI1007452A2 BRPI1007452A BRPI1007452A BRPI1007452A2 BR PI1007452 A2 BRPI1007452 A2 BR PI1007452A2 BR PI1007452 A BRPI1007452 A BR PI1007452A BR PI1007452 A BRPI1007452 A BR PI1007452A BR PI1007452 A2 BRPI1007452 A2 BR PI1007452A2
Authority
BR
Brazil
Prior art keywords
organic compounds
galenic formulations
galenic
formulations
compounds
Prior art date
Application number
BRPI1007452A
Other languages
English (en)
Inventor
Sabine Desset-Bréthes
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1007452(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI1007452A2 publication Critical patent/BRPI1007452A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1007452A 2009-01-28 2010-01-27 formulações galênicas de compostos orgânicos BRPI1007452A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28
PCT/EP2010/050886 WO2010086312A1 (en) 2009-01-28 2010-01-27 Galenic formulations of organic compounds

Publications (1)

Publication Number Publication Date
BRPI1007452A2 true BRPI1007452A2 (pt) 2016-02-16

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007452A BRPI1007452A2 (pt) 2009-01-28 2010-01-27 formulações galênicas de compostos orgânicos

Country Status (27)

Country Link
US (1) US20110287100A1 (pt)
EP (1) EP2391345B1 (pt)
JP (1) JP2012516299A (pt)
KR (1) KR20110117199A (pt)
CN (1) CN102300558A (pt)
AR (1) AR075179A1 (pt)
AU (1) AU2010209787B2 (pt)
BR (1) BRPI1007452A2 (pt)
CA (1) CA2749531A1 (pt)
CL (1) CL2011001817A1 (pt)
CO (1) CO6400184A2 (pt)
EC (1) ECSP11011289A (pt)
ES (1) ES2525648T3 (pt)
IL (1) IL213918A0 (pt)
MA (1) MA33060B1 (pt)
MX (1) MX2011007779A (pt)
MY (1) MY153852A (pt)
NZ (1) NZ593622A (pt)
PE (1) PE20110943A1 (pt)
PL (1) PL2391345T3 (pt)
PT (1) PT2391345E (pt)
RU (1) RU2535090C2 (pt)
SG (1) SG172226A1 (pt)
TN (1) TN2011000307A1 (pt)
TW (1) TWI468191B (pt)
WO (1) WO2010086312A1 (pt)
ZA (1) ZA201104489B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
JP7156945B2 (ja) 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤
US12171878B2 (en) 2018-08-10 2024-12-24 Kissei Pharmaceutical Co., Ltd. Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
CA3129383A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing aeration of suspensions during in-line mixing
CN113490486B (zh) 2019-02-22 2025-10-17 康特伦英国斯温顿捷迪斯有限公司 最小化团聚、曝气和保持包含布洛芬的药物组合物的包衣
BR112021016485A2 (pt) 2019-02-22 2021-10-13 Catalent U.K. Swindon Zydis Limited Minimização de aglomeração de material de revestimento de partícula de fármaco durante armazenamento para estabilizar tempos de desintegração de produtos farmacêuticos
AR118418A1 (es) 2019-02-22 2021-10-06 Catalent Uk Swindon Zydis Ltd Conservación de partículas ifa revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspensión acuosa
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
MX2023001004A (es) 2020-07-31 2023-03-01 Catalent Uk Swindon Zydis Ltd Composiciones farmaceuticas que comprenden un ingrediente farmaceutico activo (api) recubierto.
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
CN122206427A (zh) * 2023-11-17 2026-06-12 第一三共健康事业株式会社 固体制剂
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
MY144477A (en) 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
US20070224260A1 (en) * 2004-04-15 2007-09-27 Dr. Reddy's Laboratories Limited Dosage Form Having Polymorphic Stability
RU2407523C2 (ru) * 2004-10-08 2010-12-27 Новартис Аг Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности
EP2205279B1 (en) * 2007-09-28 2011-04-13 Novartis AG Pharmaceutical combination of aliskiren and valsartan

Also Published As

Publication number Publication date
AU2010209787A1 (en) 2011-07-14
CN102300558A (zh) 2011-12-28
CA2749531A1 (en) 2010-08-05
EP2391345A1 (en) 2011-12-07
NZ593622A (en) 2013-12-20
SG172226A1 (en) 2011-07-28
KR20110117199A (ko) 2011-10-26
TW201038300A (en) 2010-11-01
ECSP11011289A (es) 2011-09-30
RU2011135417A (ru) 2013-03-10
PE20110943A1 (es) 2012-01-22
MA33060B1 (fr) 2012-02-01
MX2011007779A (es) 2011-08-12
CO6400184A2 (es) 2012-03-15
JP2012516299A (ja) 2012-07-19
TN2011000307A1 (en) 2012-12-17
EP2391345B1 (en) 2014-09-03
ES2525648T3 (es) 2014-12-26
IL213918A0 (en) 2011-07-31
PT2391345E (pt) 2014-12-03
AU2010209787B2 (en) 2013-06-06
US20110287100A1 (en) 2011-11-24
TWI468191B (zh) 2015-01-11
PL2391345T3 (pl) 2015-03-31
AR075179A1 (es) 2011-03-16
WO2010086312A1 (en) 2010-08-05
MY153852A (en) 2015-03-31
ZA201104489B (en) 2012-02-29
HK1161125A1 (en) 2012-08-24
CL2011001817A1 (es) 2012-01-13
RU2535090C2 (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
ZA201104489B (en) Galenic formulations of organic compounds
BRPI0817442A2 (pt) Formulações galênicas de composto orgânicos
HRP20181347T1 (hr) Formulacije dvoslojne tablete
BRPI1012247A2 (pt) compostos inseticidas
SMT201600008B (it) Composti di piridazinone
BRPI1015931A2 (pt) Compostos inseticidas
PT2448582T (pt) Compostos e composições terapêuticas
LT3403654T (lt) Geriamosios kortikosteroido kompozicijos
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BRPI1012539A2 (pt) composições farmacêuticas
BRPI0715621A2 (pt) Formulações galênicas de compostos orgânicos
BRPI1009465A2 (pt) Formulação
PT2260053E (pt) Análogos de oxitocina
BR112012003868A2 (pt) Compostos orgânicos
BRPI1013941A2 (pt) compostos inseticidas
HUE052508T2 (hu) Szerves anyagból származó illékony szerves vegyületek elnyelése
IT1394400B1 (it) Composizioni farmaceutiche
SMT201600031B (it) Composti eterociclici di fenossimetile
PT2402012E (pt) Formulações líquidas de fumarato de rupatadina
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
SMT202100150T1 (it) Formulazioni migliorate
BR112012001340A2 (pt) composições farmacêuticas
CU23884B1 (es) Derivados de dibenzotiazepina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2395 DE 29-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.